Microbia, Forest ink $330M deal

Microbia is pocketing a $70 million up front payment from Forest Laboratories in exchange for a 50/50 U.S. development pact for linaclotide, an experimental therapy for irritable bowel syndrome and other gastrointestinal problems. Forest gains exclusive rights to the drug in Canada and Mexico and will help pay development costs. If all goes according to plan, Microbia will garner up to $330 million in the deal. The therapy is currently in Phase IIb. Microbia was a 2006 Fierce 15 company.

- see the release on the deal

Related Articles:
Microbia lands whopping $75M fifth round. Report
Forest Labs dumps failed stroke drug program. Report
Forest buys Cerexa in $480M deal. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.